Reported by Sreepriya, Head of Editorial & Life Sciences Research at Priya Life Science. Verified in partnership with Fleming Events for the 9th Annual Corporate Compliance & Transparency Summit in Zurich, Switzerland.
Executive Summary: Priya Life Science is proud to announce its official media partnership with Fleming Events for the flagship 9th Annual Corporate Compliance & Transparency in Life Sciences Summit. Taking place on November 17 - 18, 2026 in Zurich, Switzerland, this executive gathering convenes over 100 senior compliance leaders, chief ethics officers, legal counsels, and transparency directors from top pharmaceutical, biotechnology, and medical technology enterprises across Europe. As part of this partnership, Priya Life Science readers receive an exclusive 20% registration discount using promo code corporate20.
- Event Title: 9th Annual Corporate Compliance & Transparency in Life Sciences Summit
- Organizing Body: Fleming Events
- Official Media Partner: Priya Life Science
- Dates & Location: November 17 - 18, 2026 | Zurich, Switzerland
- Core Agenda Pillars: EU AI Act compliance, algorithmic governance, EFPIA disclosure code updates, aggregate spend automation, Fair Market Value (FMV) methodologies, and whistleblower protection.
- Exclusive Promotion: 20% discount on delegate passes using promo code corporate20.
1. Navigating AI Governance and Global Enforcement
The global pharmaceutical and medical technology sectors are undergoing an unprecedented transformation in corporate oversight. For decades, life sciences compliance focused primarily on traditional anti-bribery policies, healthcare professional (HCP) hospitality thresholds, and periodic financial audits. However, the rapid introduction of generative artificial intelligence, machine learning in clinical development, and complex commercial marketing channels has rendered legacy oversight models incomplete.
Today, compliance executives face an urgent mandate: AI Governance. Under the European Union Artificial Intelligence Act (EU AI Act), AI systems deployed in diagnostic pipelines, automated medical communications, safety signal monitoring, and promotional material generation require rigorous risk classification, technical documentation, and human oversight. Organizations failing to establish defensible AI governance before 2027 face severe financial penalties and operational disruption.
To address these critical challenges, the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit gathers distinguished ethics pioneers, regulatory leads, and legal experts to share practical strategies and battle-tested compliance frameworks.
2. Key Agenda Highlights and Expert Faculty
The two-day conference in Zurich delivers a comprehensive program covering the most urgent regulatory topics facing European and international healthcare organizations:
- The 2030 Compliance Function: Opening keynote address by Brett Hudson, Vice President of Ethics, Risk & Compliance at Novartis, addressing the evolution of compliance officers from traditional gatekeepers into strategic data-driven futurists.
- Ecosystem and Third-Party Risk: Strategic spotlight led by Bella Hovhannisyan, Chief Ethics & Compliance Officer at CSL, exploring indirect influence risks, healthcare organization (HCO) foundations, and multi-country distributor governance.
- High-Risk AI Systems & EU AI Act Alignment: Panel featuring compliance leaders from Novartis, CSL, WHO Foundation, and Amarin Corporation decoding human-in-the-loop validation, AI literacy training, and MDR/IVDR intersections.
- Global Anti-Corruption Enforcement: In-depth examination of DOJ, SEC, and European regulatory enforcement trends featuring Kersten Schmahl (CSL), Francesco Clementucci (The World Bank Group), and senior leads from Amgen and Bristol Myers Squibb.
- GDPR vs. Pharmacovigilance Retention: Practical legal roadmap led by Luca Fiormonti, Senior Privacy Counsel at Chiesi Farmaceutici, reconciling patient data erasure rights under GDPR Article 17 with mandatory drug safety tracking.
- Irish Life Sciences Compliance: Practical insights from Caroline Kelly, Founder & CEO of Ireland-based Pharma Integrity, detailing ethical culture building and HPRA regulatory alignment.
3. Corporate Compliance & Transparency Matrix
The table below provides a comprehensive summary of the core conference pillars, primary regulatory drivers, and practical operational takeaways for European biopharma leadership:
| Conference Pillar | Contributing Faculty | Primary Regulatory Driver | Operational Outcome |
|---|---|---|---|
| AI Ethics & Governance | Brett Hudson (Novartis), Alex Davison (Amarin) | EU AI Act (2026-2027), MDR/IVDR Integration | Establishes mandatory AI literacy and technical oversight for commercial and clinical teams. |
| Third-Party & HCO Governance | Bella Hovhannisyan (CSL), Babila Gipponi (BMS) | EFPIA Code of Practice, Anti-Bribery Statutes | Transforms distributor diligence and HCP entity governance across European hubs. |
| Global Anti-Corruption Analytics | Kersten Schmahl (CSL), Francesco Clementucci (World Bank) | US FCPA, UK Bribery Act, EU Integrity Directives | Equips leadership with automated transaction monitoring to defend against multi-agency probes. |
| GDPR vs. Pharmacovigilance | Luca Fiormonti (Chiesi), George Roussalis | GDPR Article 17, EMA GVP Guidelines | Resolves data retention conflicts for long-term safety data held in European repositories. |
| Patient Co-Creation & FMV | Sanja Njegic, Marlize Eckert (GCO Global), Caroline Kelly (Pharma Integrity) | EFPIA Guidelines, National Transparency Registers | Provides compliant fair market value structures for key opinion leaders and advisory boards. |
4. Strategic Synergy: Media Partnership Announcement
Through this official collaboration, Priya Life Science delivers in-depth pre-conference analysis, executive commentary, and post-summit reports to our audience of pharmaceutical executives, regulatory specialists, and life sciences decision-makers. By connecting high-level policy dialogue with daily operational reporting, both organizations support ethical leadership across the international biopharma sector.
Detailed event agendas, speaker biographies, and session schedules are available directly on the official Fleming Corporate Compliance & Transparency Summit portal.
5. Exclusive Reader Promotion: Save 20% on Registration
As part of our media partnership, Priya Life Science has arranged an exclusive 20% registration discount for our readers and partner network across all delegate pass categories.
Corporate Compliance & Transparency in Life Sciences 2026
Dates: 17-18 November 2026 | Venue: Zurich, Switzerland
Join senior ethics, compliance, privacy, and regulatory directors from Novartis, Roche, Bayer, Amgen, and BMS to master AI governance and 2027 regulatory mandates.
Scan for Mobile Pass
Direct 20% Discount Pass
6. Frequently Asked Questions (FAQ)
Q: When and where will the conference take place?
A: The 9th Annual Corporate Compliance & Transparency in Life Sciences Conference will be held on 17-18 November 2026 in Zurich, Switzerland.
Q: What is Priya Life Science's role in the Zurich summit?
A: Priya Life Science serves as an official Media Partner, providing pre-conference analysis, executive coverage, and media amplification across our life sciences platform.
Q: What key topics are covered during the two-day event?
A: Core themes include EU AI Act compliance, human-in-the-loop oversight, EFPIA transparency code updates, aggregate spend automation, Fair Market Value (FMV) rate cards, and GDPR versus pharmacovigilance data retention.
Q: How do readers claim the 20% discount on ticket registration?
A: Readers can apply promo code corporate20 during online checkout at the official Fleming Events Portal or scan the QR code featured in this article.
Q: Who should attend the Corporate Compliance Summit?
A: The summit is designed for Chief Compliance Officers (CCOs), Heads of Legal, Regulatory Affairs Directors, Data Protection Officers (DPOs), and Transparency Leads from pharmaceutical, biotech, and medical device companies.
Conclusion
As corporate governance and AI regulation redefine life sciences across Europe, the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich stands out as an essential gathering for industry leadership. Priya Life Science is pleased to support Fleming Events in advancing ethical leadership, robust compliance frameworks, and collaborative innovation across the biopharmaceutical ecosystem.
